Actio Biosciences, Inc.
Dimitrios Arkilo currently serves as the Chief Medical Officer at Actio Biosciences, Inc., a role begun in August 2024. Previously, Dimitrios held the position of Vice President and Medical Science Head of Neurology at Sage Therapeutics from August 2022 to August 2024, as well as Vice President of Clinical Development at Acadia Pharmaceuticals Inc. from July 2021 to August 2022. Prior experience includes significant roles at Takeda, serving as Executive Medical Director and Senior Medical Director across various global clinical lead positions from December 2017 to July 2021, and as Medical Director in Clinical Development at SAGE Therapeutics from July 2016 to December 2017. Dimitrios also practiced as an Attending in Pediatric Neurology and Epilepsy at the Minnesota Epilepsy Group from July 2013 to July 2016, after completing fellowships at the University of Minnesota and Tufts University-Floating Hospital for Children. Dimitrios began medical training with a Doctor of Medicine degree from Semmelweis University from 1995 to 2001.
This person is not in any teams
Actio Biosciences, Inc.
We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.